Evidence map›Paper›PMID 41900784›Full record

ArticlePharmaceutics2026

New Player in the Field of Glioblastoma Therapy: EGFRvIII-Specific Gol1 Aptamer Shows a Great Therapeutic Potential.

Fatima Dzarieva, Svetlana Pavlova, Lika Fab, Dzhirgala Shamadykova, Alexander Revishchin, Anna Alekseeva, Alexey Kopylov, Igor Pronin, Galina Pavlova

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Pharmaceutics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Fatima DzarievaInstitute of Higher Nervous Activity and Neurophysiology, Russian Academy of Sciences, 117485 Moscow, Russia.ORCID 0000-0002-2884-6142
Svetlana PavlovaInstitute of Higher Nervous Activity and Neurophysiology, Russian Academy of Sciences, 117485 Moscow, Russia.ORCID 0000-0002-9595-9358
Lika FabInstitute of Higher Nervous Activity and Neurophysiology, Russian Academy of Sciences, 117485 Moscow, Russia.
Dzhirgala ShamadykovaInstitute of Higher Nervous Activity and Neurophysiology, Russian Academy of Sciences, 117485 Moscow, Russia.ORCID 0000-0003-3665-667X
Alexander RevishchinInstitute of Higher Nervous Activity and Neurophysiology, Russian Academy of Sciences, 117485 Moscow, Russia.ORCID 0000-0002-6007-6440
Anna AlekseevaInstitute of Higher Nervous Activity and Neurophysiology, Russian Academy of Sciences, 117485 Moscow, Russia.
Alexey KopylovInstitution N. N. Burdenko National Medical Research Center of Neurosurgery of the Ministry of Health of the Russian Federation, 125047 Moscow, Russia.ORCID 0000-0003-0962-8905
Igor ProninInstitution N. N. Burdenko National Medical Research Center of Neurosurgery of the Ministry of Health of the Russian Federation, 125047 Moscow, Russia.ORCID 0000-0002-4480-0275
Galina PavlovaInstitute of Higher Nervous Activity and Neurophysiology, Russian Academy of Sciences, 117485 Moscow, Russia.ORCID 0000-0002-6885-6601

Funding

Ministry of Science and Higher Education of the Russian Federation 075-15-2024-561
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

aptamerEGFRvIIIglioblastomatargeted therapy

Identifiers

PMID41900784
PMCPMC13028680

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.